Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion, Acute Rejection of Lung Transplant (Disorder), Airway Obstruction, Rib Fractures, Acute Copd Exacerbation, Asthma COPD, Pulmonary Embolism, Hemothorax, Pneumothorax, Mesothelioma, Diaphragmatic Paralysis
Interventions: Portable Dynamic Digital Radiography (DDR); Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Transplant Rejection
Interventions: macitentan, placebo (for macitentan); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Vitreoretinal Lymphoma
Interventions: ICM ADX-2191 injection, Monthly ADX-2191 injection; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anxiety Disorders and Symptoms, Depression, Anxiety, Generalized Anxiety Disorder, Emotional Dysfunction
Interventions: Emotion Regulation Therapy: 8-session version, Emotion Regulation Therapy: 16-session version; Behavioral
Lead sponsor: Douglas Mennin; Other
Eligibility: 18 Years to 29 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Humans
Interventions: Beverage made to look like the cranberry beverage, Beverage made from cranberry compounds; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Anesthesia, Local
Interventions: Lidocaine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 30 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Psoriatic Arthritis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 59
States / cities: Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more

Conditions: Obesity
Interventions: Brief Behavioral Weight Loss (BWL), Motivation Enhanced BWL; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Metastatic Breast Cancer
Interventions: Paclitaxel+Reparixin; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Scottsdale, Arizona • Fairway, Kansas • Ann Arbor, Michigan + 1 more

Conditions: Migraine
Interventions: Mixed meal tolerance testing, Skin conductance & cold pressor test, Flow-mediated dilation testing; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions: Hydrus Microstent, Ophthalmic surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more

Conditions: End Stage Kidney Disease, End Stage Renal Disease
Interventions: Assistance to perform Peritoneal Dialysis (PD) at home; Other
Lead sponsor: Satellite Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Emeryville, California • Fremont, California • Milpitas, California + 3 more

Conditions: Stroke
Interventions: Belt Accelerations, Belt accelerations combined with an exoskeleton, Variable Stiffness treadmill; Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Thyroid Carcinoma
Interventions: Vemurafenib, serial 124I PET/CT, thyrotropin alpha; Drug · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Functional Deficits, Manipulation, Rehabilitation
Interventions: High Velocity Low Amplitude mobilization, Exercise Protocol; Other
Lead sponsor: Shenandoah University; Other
Eligibility: 16 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Winchester, Virginia

Conditions: Depression, Anhedonia
Interventions: Active RS-EFP, Sham RS-EFP; Device
Lead sponsor: GrayMatters Health Ltd.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Obesity
Interventions: Internet-based weight loss program, Yoga, Health and Wellness; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Peripheral Vascular Diseases
Interventions: Muscular Strength Training Group, Muscular Fitness Training Group; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Breast Cancer
Interventions: venlafaxine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Combination pill, Ramipril; Drug
Lead sponsor: Ferrer Internacional S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Use
Interventions: Nicotine Replacement Therapy, Counseling; Drug · Behavioral
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Gadolinium Deposition Disease
Interventions: Calcium DTPA and Zinc DTPA; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions: Cool B70 AP Coil - Active (dl-PFC), Cool B70 AP Coil- Sham (dl-PFC), Cool D-B80 AP Coil - Active (dm-PFC), Cool D-B80 AP Coil - Sham (dm-PFC), Cool B70 Treatment Coil - Active Only; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tallahassee, Florida

Search by objective public record fields.

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Emotion Regulation Therapy for Clinical Worry and Rumination

Cranberry Enhances Human Immune Function and Reduces Illness

Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Motivational Interviewing for Weight Loss With Young Adults

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Migraine and CVD Risk in Women

Safety and Effectiveness of the Hydrus Microstent

Assisted Peritoneal Dialysis: A Feasibility Study

Model-informed Patient-specific Rehabilitation Using Robotics and Neuromuscular Modeling

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Effects of Mobilization in Conjunction With Therapeutic Exercise in Participants With a History of Ankle Sprain

PRISM Neurofeedback Training for MDD Anhedonic Patients

Strategies for Improving Remote-based Weight Loss (PATH Trial)

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 3

Venlafaxine for Hot Flashes After Breast Cancer

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure

Jail-Based Use of Smoking Cessation Treatment Study

DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure

Rapid Treatment of PTSD With Accelerated Non-Invasive Brain Stimulation